NTLA Sep 2024 22.500 call
| Previous Close | 4.0000 |
| Open | 3.5000 |
| Bid | 4.6000 |
| Ask | 7.0000 |
| Strike | 22.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 3.4000 - 4.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 56 |
ZacksIntellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
GlobeNewswireIntellia Therapeutics Names Brian Goff to its Board of Directors
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. “We are very pleased to welcome Brian to our board of directors. Brian’s extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to
Simply Wall St.It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John Leonard's total...
